November 2021 Twist Bioscience Launches Revelar Biotherapeutics to Develop and Commercialize Novel COVID --(BUSINESS WIRE)--Nov. 15, 2021-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers Biopharma, a division of Twist Bioscience, that neutralizes all known variants of concern of the SARS-CoV addition, Revelar will have the ability to leverage the antibody discovery and optimization platform of Twist Biopharma to license additional antibodies for up to five targets over the next four years."

December 2022 Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to Discover and Develop Novel Therapeutic Antibodies against GPCR Targets "Collaboration aims to combine Twist’s proprietary TSE: 4565), the world leader in GPCR-focused structure-based drug design (SBDD) and development, and Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering

Aaron Sato, Chief Scientific Officer at Twist Bioscience, elaborates.

(Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel

August 2022 "August 10, 2022 Cancer Research UK is working with global biopharma Sosei Heptares on a

Trials for Treating Type 2 Diabetes and Obesity Special report 2022: Meet 20 women blazing trails in biopharma

Industry News Inversago Pharma to Participate at the 2023 SVB Securities Global BioPharma Conference

Twist Bioscience and Astellas Enter into Multitarget Antibody Discovery Research Collaboration Neurocrine

AEF0117 for the treatment of cannabis use disorder Orion Biotechnology will be presenting at the 19th Biopharma

Pharmaceuticals Business in Japan and APAC (ex-China), Accelerating its Transformation into a Fully Integrated Biopharmaceutical

(NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative

(Nasdaq:TRVN), a biopharmaceutical company focused on the development and commercialization of novel

., (NASDAQ: CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune

Cambridge, UK, 22 July 2022 – Sosei Group Corporation (“the Company”; TSE: 4565), an international biopharmaceutical

., a venture-backed clinical stage international biopharmaceutical company with an innovative approach

Japan, Cambridge, UK and New York, USA – May 17, 2022 – Sosei Group Corporation, the international biopharmaceutical

best-in-class and first-in-class immuno-oncology programs STRASBOURG, France & MONTREAL- Domain Therapeutics, a biopharmaceutical

(Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel

(Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel

Strasbourg and Bordeaux, France, March 10, 2022 – Domain Therapeutics, a biopharmaceutical company specializing

., a clinical-stage global biopharmaceutical company developing novel oral therapeutics to treat a wide

., Jan. 27, 2022 A biopharmaceutical company focused on the development and commercialization of novel

Carola Weiss is a Senior Executive with more than 20 years of international experience in the biopharmaceutical

. 💊 InterAx Biotech AG discovery platform was already successfully applied in projects with biopharmaceutical

(Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel